atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) Post published:April 13, 2023 Post category:Press Release
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights Post published:March 24, 2023 Post category:Press Release
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates Post published:March 6, 2023 Post category:Press Release
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference Post published:March 1, 2023 Post category:Press Release
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 Post published:January 12, 2023 Post category:Press Release
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression Post published:January 6, 2023 Post category:Press Release
atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial Post published:January 6, 2023 Post category:Analysis
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital Post published:December 16, 2022 Post category:Press Release
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer Post published:November 29, 2022 Post category:Press Release
Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout Post published:November 17, 2022 Post category:Analysis